Apnimed (APMD) Stock Forecast: StockMap's 2-Week Call

APMD stock forecast: StockMap's model leans Underperform on Apnimed for the two weeks after the Nov 16 close, toward APMD trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on APMD since Aug 21; by chance, a call on the same dates was right 62% of the time.

Apnimed last closed at $16.28, -3.78% on the session.

Against the IVW growth benchmark the position is -1.16% over the forecast window.

Apnimed's market cap is $677.77M as of November 16, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).

Where APMD sits: sized by market cap, coloured by the day's move.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

37 daily calls for APMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Apnimed is classified under Health Care / Pharmaceuticals.

StockMap tracks Apnimed as the 69th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 76 Moderate Underperform, 47 Neutral, 29 Strong Underperform and 1 Moderate Outperform.

On that composite Apnimed ranks 113th of 153 in the group, against a group median of -0.33.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 16, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Apnimed (APMD) — StockMap 2-week forecast & tracked accuracy